Aptabio Therapeutics, a developer of intractable cancer and diabetes complications, announced Monday that it will present preclinical results on the effectiveness of its treatment for Parkinson's disease, APX-NEW, in animal models at the Society of Neuroscience (SFN).

The SFN is a large-scale meeting where more than 30,000 experts who study the brain and nervous system from 80 countries around the world share the latest research findings. This year's SFN is being held in Washington, U.S., from Nov. 11 to 15.

Parkinson's disease is a degenerative brain disorder in which neurons in the substantia nigra (SN) of the midbrain gradually die, resulting in low levels of dopamine, which affects cognitive function as well as movement disorders.

The main pathological feature of the disease is the abnormal accumulation of alpha-synuclein in the nervous system, resulting in excessive accumulation of protein aggregation called Lewy body.

Recently, alpha-synuclein has become an important factor in the development of new treatments for Parkinson's disease, as it has been reported to spread widely to different parts of the brain depending on the severity of the disease.

At SFN, Aptabio Therapeutics will present the study that explains the possibility of treating Parkinson's disease by reducing alpha-synuclein, a major contributor to the disease, through modulation of oxidative stress.

The study was published in the International Journal of Molecular Sciences, titled "A Novel NOX Inhibitor Alleviates Parkinson's Disease Pathology in PFF-Injected Mice".

Aptabio's APX-NEW is an oral medication that offers competitive advantages in cost and ease of administration, the company said.